Bimatoprost- Optifye Therapeutics
Alternative Names: Bimatoprost PFLatest Information Update: 20 Apr 2022
At a glance
- Originator Optifye Therapeutics
- Class Amides; Antiglaucomas; Lipids; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2alpha receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Glaucoma
Most Recent Events
- 04 Apr 2022 Clinical trials in glaucoma in Switzerland (Ophthalmic) before April 2022 (Optifye Therapeutics pipeline, April 2022)